Compare Stocks: UTHR, REGN, ARGX, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$856.94 -2.2%	$882.53	$644.63 ▼ $953.58	$54.80B	0.46	291,848 shs	171,353 shs
NTRA Natera	$310.78 -1.6%	$261.87	$152.62 ▼ $326.03	$45.54B	1.51	1.26 million shs	1.52 million shs
REGN Regeneron Pharmaceuticals	$805.97 +1.0%	$672.43	$541.00 ▼ $821.11	$82.16B	0.22	848,937 shs	709,726 shs
UTHR United Therapeutics	$501.27 -2.0%	$536.95	$302.19 ▼ $609.35	$21.95B	0.59	515,673 shs	408,040 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-2.18%	-2.10%	-0.29%	+7.21%	+32.53%
NTRA Natera	-1.64%	+17.11%	+13.98%	+66.76%	+97.07%
REGN Regeneron Pharmaceuticals	+1.00%	+4.39%	+22.84%	+15.43%	+43.53%
UTHR United Therapeutics	-2.04%	-5.94%	-4.82%	-11.84%	+61.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$856.94 -2.2%	$882.53	$644.63 ▼ $953.58	$54.80B	0.46	291,848 shs	171,353 shs
NTRA Natera	$310.78 -1.6%	$261.87	$152.62 ▼ $326.03	$45.54B	1.51	1.26 million shs	1.52 million shs
REGN Regeneron Pharmaceuticals	$805.97 +1.0%	$672.43	$541.00 ▼ $821.11	$82.16B	0.22	848,937 shs	709,726 shs
UTHR United Therapeutics	$501.27 -2.0%	$536.95	$302.19 ▼ $609.35	$21.95B	0.59	515,673 shs	408,040 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-2.18%	-2.10%	-0.29%	+7.21%	+32.53%
NTRA Natera	-1.64%	+17.11%	+13.98%	+66.76%	+97.07%
REGN Regeneron Pharmaceuticals	+1.00%	+4.39%	+22.84%	+15.43%	+43.53%
UTHR United Therapeutics	-2.04%	-5.94%	-4.82%	-11.84%	+61.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,056.89	23.33% Upside
NTRA Natera	2.82	Moderate Buy	$319.38	2.77% Upside
REGN Regeneron Pharmaceuticals	2.62	Moderate Buy	$793.74	-1.52% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	28.87% Upside

Current Analyst Ratings Breakdown

Latest UTHR, REGN, ARGX, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	NTRA Natera	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$315.00 ➝ $365.00
8/12/2026	NTRA Natera	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$305.00 ➝ $350.00
8/12/2026	NTRA Natera	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $360.00
8/12/2026	NTRA Natera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$249.00 ➝ $363.50
8/10/2026	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$355.00
8/7/2026	NTRA Natera	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $340.00
8/7/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $350.00
8/7/2026	NTRA Natera	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$348.00
8/7/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$375.00
8/6/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$515.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	12.62	$20.87 per share	41.06	$134.54 per share	6.37
NTRA Natera	$2.31B	19.42	N/A	N/A	$12.38 per share	25.10
REGN Regeneron Pharmaceuticals	$14.34B	5.79	$42.40 per share	19.01	$308.01 per share	2.62
UTHR United Therapeutics	$3.18B	6.76	$32.32 per share	15.51	$149.22 per share	3.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	32.91	23.57	1.08	32.19%	43.59%	36.66%	N/A
NTRA Natera	-$208.16M	-$1.36	N/A	10,359.33	N/A	-7.11%	-11.82%	-8.19%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.92	15.95	1.36	27.86%	13.47%	10.34%	10/28/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.93	15.91	1.73	41.56%	20.18%	17.98%	N/A

Latest UTHR, REGN, ARGX, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.47%	N/A	9.29%	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest UTHR, REGN, ARGX, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.51%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
NTRA Natera	N/A	2.96	2.83
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
NTRA Natera	99.90%
REGN Regeneron Pharmaceuticals	83.31%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
NTRA Natera	5.05%
REGN Regeneron Pharmaceuticals	6.97%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

UTHR, REGN, ARGX, and NTRA Headlines

Recent News About These Companies

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 13 at 7:06 PM | marketbeat.com

United Therapeutics’s Q2 earnings call: Our top 5 analyst questions

August 12 at 1:46 PM | msn.com

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

August 12 at 1:46 PM | fool.com

Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry

August 12 at 10:31 AM | investors.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 11 at 4:06 AM | insidertrades.com

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,291,515.00 in Stock

August 9, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,928,030.00 in Stock

August 9, 2026 | americanbankingnews.com

Royal Bank Of Canada Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $677.00

August 9, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR

August 9, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Sees Strong Trading Volume - Should You Buy?

August 7, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

August 7, 2026 | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,902,570.00 in Stock

August 7, 2026 | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE

August 7, 2026 | marketbeat.com

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

August 6, 2026 | finance.yahoo.com

Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 6, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 6, 2026 | marketbeat.com

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

August 6, 2026 | tipranks.com

UTHR Q2 2026 deep dive: Product pipeline developments offset competitive pressures

August 6, 2026 | msn.com

Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

August 6, 2026 | marketbeat.com

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

August 6, 2026 | zacks.com

United Therapeutics Balances Tyvaso Woes With Pipeline Wins

August 5, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, REGN, ARGX, and NTRA Company Descriptions

argenex NASDAQ:ARGX

$856.94 -19.06 (-2.18%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$859.96 +3.02 (+0.35%)

As of 04:17 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Natera NASDAQ:NTRA

$310.78 -5.18 (-1.64%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$310.77 -0.01 (0.00%)

As of 06:53 AM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals NASDAQ:REGN

$805.97 +7.98 (+1.00%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$808.10 +2.13 (+0.26%)

As of 06:24 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

United Therapeutics NASDAQ:UTHR

$501.27 -10.45 (-2.04%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$501.29 +0.02 (+0.00%)

As of 08/13/2026 06:00 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTHR, REGN, ARGX, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTHR, REGN, ARGX, and NTRA Earnings

Compare Dividends

Latest UTHR, REGN, ARGX, and NTRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTHR, REGN, ARGX, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, REGN, ARGX, and NTRA Company Descriptions

argenex NASDAQ:ARGX

Natera NASDAQ:NTRA

Regeneron Pharmaceuticals NASDAQ:REGN

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTHR, REGN, ARGX, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTHR, REGN, ARGX, and NTRA Earnings

Compare Dividends

Latest UTHR, REGN, ARGX, and NTRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTHR, REGN, ARGX, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, REGN, ARGX, and NTRA Company Descriptions

argenex NASDAQ:ARGX

Natera NASDAQ:NTRA

Regeneron Pharmaceuticals NASDAQ:REGN

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools